Search research articles
Contact Us
Filters
Showing results (1-10 of 40) with videos related to
Page
of 4
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
September 20, 2006
Cutting edge: Paracrine, but not autocrine, IL-2 signaling is sustained during early antiviral CD4 T cell response
Meixiao Long, Adam J Adler
Immunological Investigations
|
October 19, 2022
Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement
Meixiao Long, Alice S Mims, Zihai Li
Blood Advances
|
October 23, 2023
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment
Lingling Wang, Vincent Leach, Natarajan Muthusamy, et al.
Cellular Immunology
|
November 12, 2003
Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentials
Meixiao Long, Amy D Higgins, Marianne A Mihalyo, et al.
Immunity
|
October 30, 2008
Differential role of the transcription factor NF-kappaB in selection and survival of CD4+ and CD8+ thymocytes
Eijiro Jimi, Ian Strickland, Reinhard E Voll, et al.
Journal of Clinical Pharmacology
|
September 3, 2020
CD33-Targeted Therapies: Beating the Disease or Beaten to Death?
Joseph E Maakaron, John Rogosheske, Meixiao Long, et al.
Immunity
|
January 13, 2010
Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor
Meixiao Long, Sung-Gyoo Park, Ian Strickland, et al.
Journal of Leukocyte Biology
|
October 17, 2008
The IKK-neutralizing compound Bay11 kills supereffector CD8 T cells by altering caspase-dependent activation-induced cell death
Seung-Joo Lee, Meixiao Long, Adam J Adler, et al.
Immunity
|
November 16, 2010
T regulatory cells maintain intestinal homeostasis by suppressing γδ T cells
Sung-Gyoo Park, Ramkumar Mathur, Meixiao Long, et al.
Molecular Cancer
|
May 10, 2024
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy
Po-Lan Su, Karthik Chakravarthy, Naoki Furuya, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 40) with videos related to
Sort By:
Page
of 4
Journal of Immunology (Baltimore, Md. : 1950)
|
September 20, 2006
Cutting edge: Paracrine, but not autocrine, IL-2 signaling is sustained during early antiviral CD4 T cell response
Meixiao Long, Adam J Adler
Immunological Investigations
|
October 19, 2022
Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement
Meixiao Long, Alice S Mims, Zihai Li
Blood Advances
|
October 23, 2023
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment
Lingling Wang, Vincent Leach, Natarajan Muthusamy, et al.
Cellular Immunology
|
November 12, 2003
Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentials
Meixiao Long, Amy D Higgins, Marianne A Mihalyo, et al.
Immunity
|
October 30, 2008
Differential role of the transcription factor NF-kappaB in selection and survival of CD4+ and CD8+ thymocytes
Eijiro Jimi, Ian Strickland, Reinhard E Voll, et al.
Journal of Clinical Pharmacology
|
September 3, 2020
CD33-Targeted Therapies: Beating the Disease or Beaten to Death?
Joseph E Maakaron, John Rogosheske, Meixiao Long, et al.
Immunity
|
January 13, 2010
Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor
Meixiao Long, Sung-Gyoo Park, Ian Strickland, et al.
Journal of Leukocyte Biology
|
October 17, 2008
The IKK-neutralizing compound Bay11 kills supereffector CD8 T cells by altering caspase-dependent activation-induced cell death
Seung-Joo Lee, Meixiao Long, Adam J Adler, et al.
Immunity
|
November 16, 2010
T regulatory cells maintain intestinal homeostasis by suppressing γδ T cells
Sung-Gyoo Park, Ramkumar Mathur, Meixiao Long, et al.
Molecular Cancer
|
May 10, 2024
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy
Po-Lan Su, Karthik Chakravarthy, Naoki Furuya, et al.
Page
of 4